Vaxart Inc.
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform. Their mission is to create transformative vaccines that are easier to distribute and administer, aiming to improve global public health by addressing common viral infections.
Vaxart Inc.
170 Harbor Way, Suite 300, South San Francisco, CA 94080
Patents
Formulations for small intestinal delivery of RSV and norovirus antigens
2025-01-07 • US-12186407-B2
View DetailsFormulations for small intestinal delivery of RSV and norovirus antigens
2022-09-06 • US-11433146-B2
View DetailsMethod for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
2018-03-06 • US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
2017-10-31 • US-9802926-B2
View DetailsWhat We Do
Vaxart's oral COVID-19 vaccine pill is designed to provide longer protection from infection, broader protection against variants, and reduce virus transmission. It is currently in Phase II trials, making Vaxart the only company in the world to reach this stage with a COVID-19 vaccine pill.
Vaxart is developing a pill vaccine for norovirus, which is the leading cause of acute viral gastroenteritis. The vaccine has shown robust immune responses in Phase 1 studies and is currently undergoing further trials.
Vaxart has completed Phase 1 trials for an H1N1 influenza A strain and an influenza B strain, demonstrating safety and immune responses that correlate with protection from influenza.
Vaxart is developing a therapeutic vaccine for human papillomavirus (HPV), targeting infections that cause cervical dysplasia and cancer.